Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Recovery of NK(CD56+CD3-) Cells after One Year of Tenofovir Therapy for Chronic Hepatitis B Infection

  • Lee, Hwan Hee (Department of Pharmacy, College of Pharmacy, Duksung Women's University) ;
  • Kang, Hyojeung (College of Pharmacy, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University) ;
  • Cho, Hyosun (Department of Pharmacy, College of Pharmacy, Duksung Women's University)
  • Received : 2017.01.31
  • Accepted : 2017.03.24
  • Published : 2017.06.28
Download PDF
⟨ Previous Next ⟩

Abstract

Natural killer (NK) cells have been reported to be dysfunctional in chronic hepatitis B (CHB) infection. However, the functional recovery of NK cells under antiviral therapeutic agents in CHB was not clearly understood. In this study, we investigated the phenotypic changes of NK(CD56+CD3-) cells in terms of their functional markers (CD16, NKG2A, NKG2D) during tenofovir therapy in CHB. The frequency of NK(CD56+CD3-) cells in CHB patients was significantly increased after 12 months of tenofovir therapy when compared with baseline. The expression levels of CD16+/CD56+CD3- and NKG2A+/CD56+CD3- cells were also affected by tenofovir treatment. In addition, there was a positive correlation between the proportion of NK(CD56+CD3-) cells and HBV DNA (log copies/ml) in CHB patients.

Keywords

References

  1. Pungpapong S, Kim WR, Poterucha JJ. 2007. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin. Proc. 82: 967-975. https://doi.org/10.4065/82.8.967
  2. Bertoletti A, Naoumov NV. 2003. Translation of immunological knowledge into better treatments of chronic hepatitis B. J. Hepatol. 39: 115-124. https://doi.org/10.1016/S0168-8278(03)00126-0
  3. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81: 4215-4225. https://doi.org/10.1128/JVI.02844-06
  4. Rehermann B, Pasquinelli C, Mosier SM, Chisari FV. 1995. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J. Clin. Invest. 96: 1527-1534. https://doi.org/10.1172/JCI118191
  5. Guillermet C, Pernollet M, Zarski JP, Marche PN, Leroy V, Jouvin-Marche E. 2009. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J. Hepatol. 51: 458-467. https://doi.org/10.1016/j.jhep.2009.05.030
  6. Bonorino P, Ramzan M, Camous X, Dufeu-Duchesne T, Thelu MA, Sturm N, et al. 2000. Innate and adaptive lymphoid cells in the human liver. Immunol. Rev. 174: 5-20. https://doi.org/10.1034/j.1600-0528.2002.017416.x
  7. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49. https://doi.org/10.1126/science.1198687
  8. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E. 2007. The trafficking of natural killer cells. Immunol. Rev. 220: 169-182. https://doi.org/10.1111/j.1600-065X.2007.00563.x
  9. Lanier LL. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immun. 9: 495-502.
  10. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, et al. 2000. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32: 1117-1124. https://doi.org/10.1053/jhep.2000.19324
  11. Mondelli MU, Varchetta S, Oliviero B. 2010. Natural killer cells in viral hepatitis: facts and controversies. Eur. J. Clin. Invest. 40: 851-863. https://doi.org/10.1111/j.1365-2362.2010.02332.x
  12. Rehermann B. 2013. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat. Med. 19: 859-868. https://doi.org/10.1038/nm.3251
  13. Mondelli MU, Oliviero B, Mele D, Mantovani S, Gazzabin C, Varchetta S. 2012. Natural killer cell functional dichotomy: a feature of chronic viral hepatitis?. Front. Immunol. 3: 351.
  14. Maini MK, Peppa D. 2013. NK cells: a double-edged sword in chronic hepatitis B virus infection. Front. Immunol. 4: 57.
  15. Matthews GV, Cooper DA, Dore GJ. 2007. Improvements in parameters of end-stage liver disease in patients with HIV/ HBV-related cirrhosis treated with tenofovir. Antiviral Ther. 12: 119-122.
  16. Stephan C, Dauer B, Khaykin P, Stuermer M, Gute P, Klauke S, et al. 2009. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV- 1 infected patients: salvage therapy or backbone only? Curr. HIV Res. 7: 320-326. https://doi.org/10.2174/157016209788348010
  17. Stelma F, de Niet A, Tempelmans Plat-Sinnige MJ, Jansen L, Takkenberg RB, Reesink HW, et al. 2015. Natural killer cell characteristics in patients with chronic hepatitis B virus (HBV) infection are associated with HBV surface antigen clearance after combination treatment with pegylated interferon alfa-2a and adefovir. J. Infect. Dis. 212: 1042-1051. https://doi.org/10.1093/infdis/jiv180
  18. Zhao PW, Jia FY, Shan YX, Ji HF, Feng JY, Niu JQ, et al. 2013. Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir. Clin. Exp. Pharmacol. Physiol. 40: 190-196. https://doi.org/10.1111/1440-1681.12048
  19. Ma L, Cai YJ, Yu L, Feng JY, Wang J, Li C, et al. 2013. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B. Antimicrob. Agents Chemother. 57: 1304-1311. https://doi.org/10.1128/AAC.02181-12
  20. Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM. 2010. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J. Hepatol. 54: 209-218.
  21. Cho H. 2013. Phenotypic characteristics of natural killer cells in acute hepatitis. J. Microbiol. 51: 247-251. https://doi.org/10.1007/s12275-013-2522-1
  22. Meier UC, Owen RE, Taylor E, Worth A, Naoumov N, Willberg C, et al. 2005. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J. Virol. 79: 12365-12374. https://doi.org/10.1128/JVI.79.19.12365-12374.2005
  23. Golden-Mason L, Bambha KM, Cheng L, Howell CD, Taylor MW, Clark PJ, et al. 2011. Natural killer inhibitory receptor expression associated with treatment failure and interleukin- 28B genotype in patients with chronic hepatitis C. Hepatology 54: 1559-1569. https://doi.org/10.1002/hep.24556

Cited by

  1. Improved Anti-Cancer Effect of Curcumin on Breast Cancer Cells by Increasing the Activity of Natural Killer Cells vol.28, pp.6, 2017, https://doi.org/10.4014/jmb.1801.01074
  2. Relationship Between Chronic Hepatitis B Virus Infection and Nature Killer Cells vol.32, pp.6, 2017, https://doi.org/10.1089/vim.2018.0131
  3. Undaria pinnatifida Fucoidan-Rich Extract Recovers Immunity of Immunosuppressed Mice vol.30, pp.3, 2017, https://doi.org/10.4014/jmb.1908.08026
  4. Rapid Recovery in COVID-19 Patients with Chronic Hepatitis B Virus Infection Treated with Tenofovir Disoproxil Fumarate vol.n, pp.None, 2017, https://doi.org/10.14218/jcth.2020.00129
  5. Pegylated Interferon-ɑ (IFN-ɑ) Enhances the Inhibitory Effect of Natural Killer Cells on Regulatory T Cells via IFN-γ in Chronic Hepatitis B vol.224, pp.11, 2017, https://doi.org/10.1093/infdis/jiab216